Pluri (PLUR) Restructuring Costs (2023 - 2024)

Pluri (PLUR) posted quarterly Restructuring Costs of -$165000.0 for Q2 2024, down 1750.0% quarter-over-quarter from $10000.0 in Q1 2024.

Pluri (PLUR) Restructuring Costs (2023 - 2024) Analysis & Trends

Pluri (PLUR) has reported Restructuring Costs for 2 consecutive years, with -$165000.0 the latest figure, recorded in Q2 2024.

In Q2 2024, Restructuring Costs changed N/A year-over-year to -$165000.0; the TTM figure through Jun 2024 stood at $249000.0 (changed N/A YoY), while the FY2025 annual figure was $2000.0, down 96.55% from the prior year.
Restructuring Costs slipped to -$165000.0 in Q2 2024 per PLUR's latest filing, from $10000.0 in the prior quarter.
Across five years, Restructuring Costs topped out at $310000.0 in Q1 2023 and bottomed at -$165000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Pluri	16.11 Mn	3.63 Mn	86,000.00

Download Data